Literature DB >> 22936217

Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Alison M Karst1, Ronny Drapkin.   

Abstract

Primary human fallopian tube secretory epithelial cell (FTSEC) cultures are useful for studying normal fallopian tube epithelial biology, as well as for developing models of fallopian tube disease, such as cancer. Because of the limited ability of primary human FTSECs to proliferate in vitro, it is necessary to immortalize them in order to establish a cell line that is suitable for long-term culture and large-scale in vitro experimentation. This protocol describes the isolation of FTSECs from human fallopian tube tissue, conditions for primary FTSEC culture and techniques for establishing immortal FTSEC lines. The entire process, from primary cell isolation to establishment of an immortal cell line, may take up to 2 months. Once established, immortal FTSECs can typically be maintained for at least 30 passages.

Entities:  

Mesh:

Year:  2012        PMID: 22936217     DOI: 10.1038/nprot.2012.097

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  28 in total

1.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

Review 2.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

3.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Authors:  Ellen L Goode; Georgia Chenevix-Trench; Honglin Song; Susan J Ramus; Maria Notaridou; Kate Lawrenson; Martin Widschwendter; Robert A Vierkant; Melissa C Larson; Susanne K Kjaer; Michael J Birrer; Andrew Berchuck; Joellen Schildkraut; Ian Tomlinson; Lambertus A Kiemeney; Linda S Cook; Jacek Gronwald; Montserrat Garcia-Closas; Martin E Gore; Ian Campbell; Alice S Whittemore; Rebecca Sutphen; Catherine Phelan; Hoda Anton-Culver; Celeste Leigh Pearce; Diether Lambrechts; Mary Anne Rossing; Jenny Chang-Claude; Kirsten B Moysich; Marc T Goodman; Thilo Dörk; Heli Nevanlinna; Roberta B Ness; Thorunn Rafnar; Claus Hogdall; Estrid Hogdall; Brooke L Fridley; Julie M Cunningham; Weiva Sieh; Valerie McGuire; Andrew K Godwin; Daniel W Cramer; Dena Hernandez; Douglas Levine; Karen Lu; Edwin S Iversen; Rachel T Palmieri; Richard Houlston; Anne M van Altena; Katja K H Aben; Leon F A G Massuger; Angela Brooks-Wilson; Linda E Kelemen; Nhu D Le; Anna Jakubowska; Jan Lubinski; Krzysztof Medrek; Anne Stafford; Douglas F Easton; Jonathan Tyrer; Kelly L Bolton; Patricia Harrington; Diana Eccles; Ann Chen; Ashley N Molina; Barbara N Davila; Hector Arango; Ya-Yu Tsai; Zhihua Chen; Harvey A Risch; John McLaughlin; Steven A Narod; Argyrios Ziogas; Wendy Brewster; Aleksandra Gentry-Maharaj; Usha Menon; Anna H Wu; Daniel O Stram; Malcolm C Pike; Jonathan Beesley; Penelope M Webb; Xiaoqing Chen; Arif B Ekici; Falk C Thiel; Matthias W Beckmann; Hannah Yang; Nicolas Wentzensen; Jolanta Lissowska; Peter A Fasching; Evelyn Despierre; Frederic Amant; Ignace Vergote; Jennifer Doherty; Rebecca Hein; Shan Wang-Gohrke; Galina Lurie; Michael E Carney; Pamela J Thompson; Ingo Runnebaum; Peter Hillemanns; Matthias Dürst; Natalia Antonenkova; Natalia Bogdanova; Arto Leminen; Ralf Butzow; Tuomas Heikkinen; Kari Stefansson; Patrick Sulem; Sören Besenbacher; Thomas A Sellers; Simon A Gayther; Paul D P Pharoah
Journal:  Nat Genet       Date:  2010-09-19       Impact factor: 38.330

4.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

Review 5.  Precursors to pelvic serous carcinoma and their clinical implications.

Authors:  Ann K Folkins; Elke A Jarboe; Michael H Roh; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

Review 6.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

Review 7.  Role of genetic polymorphisms and ovarian cancer susceptibility.

Authors:  Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Journal:  Mol Oncol       Date:  2009-02-04       Impact factor: 6.603

8.  A simple and quick method to concentrate MSCV retrovirus.

Authors:  Eiki Kanbe; Dong-Er Zhang
Journal:  Blood Cells Mol Dis       Date:  2004 Jul-Aug       Impact factor: 3.039

9.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

10.  Ex vivo culture of primary human fallopian tube epithelial cells.

Authors:  Susan Fotheringham; Keren Levanon; Ronny Drapkin
Journal:  J Vis Exp       Date:  2011-05-09       Impact factor: 1.355

View more
  67 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

3.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

4.  Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.

Authors:  Mark A Eckert; Shawn Pan; Kyle M Hernandez; Rachel M Loth; Jorge Andrade; Samuel L Volchenboum; Pieter Faber; Anthony Montag; Ricardo Lastra; Marcus E Peter; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Discov       Date:  2016-10-07       Impact factor: 39.397

5.  Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.

Authors:  Alison M Kurimchak; Carlos Herrera-Montávez; Jennifer Brown; Katherine J Johnson; Valerie Sodi; Nishi Srivastava; Vikas Kumar; Safoora Deihimi; Shane O'Brien; Suraj Peri; Gina M Mantia-Smaldone; Angela Jain; Ryan M Winters; Kathy Q Cai; Jonathan Chernoff; Denise C Connolly; James S Duncan
Journal:  Sci Signal       Date:  2020-02-18       Impact factor: 8.192

6.  The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Authors:  Jane Antony; Elisa Zanini; Zoe Kelly; Tuan Zea Tan; Evdoxia Karali; Mohammad Alomary; Youngrock Jung; Katherine Nixon; Paula Cunnea; Christina Fotopoulou; Andrew Paterson; Sushmita Roy-Nawathe; Gordon B Mills; Ruby Yun-Ju Huang; Jean Paul Thiery; Hani Gabra; Chiara Recchi
Journal:  EMBO Rep       Date:  2018-06-15       Impact factor: 8.807

7.  Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.

Authors:  Kevin M Elias; Megan M Emori; Eniko Papp; Emily MacDuffie; Gottfried E Konecny; Victor E Velculescu; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2015-08-29       Impact factor: 5.482

8.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

Review 9.  Three-dimensional modeling of ovarian cancer.

Authors:  Erin A White; Hilary A Kenny; Ernst Lengyel
Journal:  Adv Drug Deliv Rev       Date:  2014-07-14       Impact factor: 15.470

10.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.